Usmani, Saad Z.Facon, ThierryHungria, VaniaBahlis, Nizar J.Venner, Christopher P.Braunstein, MarcPour, LudekMartÃ, Josep M.Basu, SupratikCohen, Yael C.Matsumoto, MorioSuzuki, KenshiHulin, CyrilleGrosicki, SebastianLegiec, WojciechBeksac, MeralMaiolino, AngeloTakamatsu, HiroyukiPerrot, AuroreTurgut, MehmetAhmadi, TahamtanLiu, WeipingWang, JianpingChastain, KatherineVermeulen, JessicaKrevvata, MariaLopez-Masi, LorenaCarey, JodiRowe, MelissaCarson, RobinZweegman, Sonja2025-09-092025-09-092025-12-31Usmani, S.Z., Facon, T., Hungria, V. et al. (in press) A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant. Future Oncology.1479-6694https://wlv.openrepository.com/handle/2436/626067This is an author's accepted manuscript due to be published by Taylor & Francis in Future Oncology [date tbc], available online at [link tbc]. The accepted manuscript may differ from the final published version.application/pdfenCEPHEUSdaratumumabD-VRdmultiple myelomanewly diagnosedtransplant ineligibletransplant deferredA plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplantJournal articleFuture Oncology